Page 29 - Read Online

Mathieu et al. Metab Target Organ Damage 2022;2:15 https://dx.doi.org/10.20517/mtod.2022.16 Page 11 of 11

anti-CD3 restores tolerance outside the window of acute type 1 diabetes diagnosis. Front Immunol 2020;11:1103. DOI PubMed
PMC
55. Tavira B, Barcenilla H, Wahlberg J, Achenbach P, Ludvigsson J, Casas R. Intralymphatic glutamic acid decarboxylase-alum
administration induced Th2-like-specific immunomodulation in responder patients: a pilot clinical trial in type 1 diabetes. J Diabetes
Res 2018;2018:9391845. DOI PubMed PMC
56. von Herrath M, Bain SC, Bode B, et al. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults
with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol
2021;9:212-24. DOI PubMed
57. Shoda LK, Young DL, Ramanujan S, et al. A comprehensive review of interventions in the NOD mouse and implications for
translation. Immunity 2005;23:115-26. DOI PubMed
58. Feutren G, Assan R, Karsenty G, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent
onset. Lancet 1986;328:119-24. DOI PubMed
59. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-
lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-52. DOI PubMed PMC
60. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al; Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to preserve beta-cell
function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care
2010;33:826-32. DOI PubMed PMC
61. Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a
randomised, double-blind, placebo-controlled trial. Lancet 2011;378:412-9. DOI PubMed PMC
62. Herold KC, Gitelman SE, Ehlers MR, et al; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide
responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline
identify a subgroup of responders. Diabetes 2013;62:3766-74. DOI PubMed PMC
63. Rigby MR, Dimeglio LA, Rendell MS, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study):
12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 2013;1:284-94. DOI
PubMed PMC
64. Piemonti L, Keymeulen B, Gillard P, et al. Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset
type 1 diabetes: a multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2022;24:1840-9. DOI
PubMed
65. Prevention Trial--Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med
2002;346:1685-91. DOI
66. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention
trial--type 1. Diabetes Care 2005;28:1068-76. DOI PubMed
67. Näntö-salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and
autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008;372:1746-55. DOI
PubMed
68. Bonifacio E, Ziegler AG, Klingensmith G, et al; Pre-POINT Study Group. Effects of high-dose oral insulin on immune responses in
children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA 2015;313:1541-9. DOI PubMed
69. Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ; Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study
Group. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA
2017;318:1891-902. DOI PubMed PMC
70. Larsson H, Lundgren M, Jonsdottir B, Cuthbertson D, Krischer J; DiAPREV-IT Study Group. Safety and efficacy of autoantigen-
specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for
type 1 diabetes: a randomized clinical trial. Pediatr Diabetes 2018;19:410-9. DOI PubMed
71. Assfalg R, Knoop J, Hoffman KL, et al. Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled
trial. Diabetologia 2021;64:1079-92. DOI PubMed PMC
72. Ludvigsson J, Sumnik Z, Pelikanova T, et al. Intralymphatic glutamic acid decarboxylase with vitamin D supplementation in recent-
onset type 1 diabetes: a double-blind, randomized, placebo-controlled phase IIb trial. Diabetes Care 2021;44:1604-12. DOI PubMed
PMC